<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD8 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 8</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD8</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 8</td></tr>
<tr><td class="label">Chromosome</td><td>10p11.21</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8325</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000177283</td></tr>
<tr><td class="label">OMIM ID</td><td>605467</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9H6Y5</td></tr>
<tr><td class="label">Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Cancer</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD8 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 8</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD8</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 8</td></tr>
<tr><td class="label">Chromosome</td><td>10p11.21</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8325</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000177283</td></tr>
<tr><td class="label">OMIM ID</td><td>605467</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9H6Y5</td></tr>
<tr><td class="label">Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Cancer</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>
FZD8 (Frizzled Class Receptor 8) is a member of the Frizzled family of seven-transmembrane G protein-coupled receptors that function as primary receptors for Wnt ligands. FZD8 plays critical roles in embryonic development, tissue patterning, and adult tissue homeostasis through activation of both canonical Wnt/β-catenin signaling and non-canonical Wnt pathways including planar cell polarity (PCP) and Wnt/Ca²⁺ signaling. In the nervous system, FZD8 is expressed throughout development and in adult brain regions including the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [cerebellum](/brain-regions/cerebellum), where it regulates neural stem cell proliferation, neuronal differentiation, synapse formation, and synaptic plasticity. Emerging evidence demonstrates that FZD8 and Wnt signaling dysregulation contribute to the pathogenesis of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and tauopathies, making FZD8 a potential therapeutic target for disease modification [@l'italien2019].
The FZD8 gene spans approximately 35 kb on chromosome 10p11.21 and consists of 10 exons encoding a 694-amino acid protein with a molecular weight of approximately 75 kDa. Like other Frizzled receptors, FZD8 possesses the characteristic architecture of class F GPCRs:
Extracellular Domain (N-terminus): The N-terminal cysteine-rich domain (CRD) contains 10 conserved cysteine residues forming disulfide bonds that create a compact ligand-binding module. The CRD specifically recognizes Wnt ligands and determines ligand-binding affinity and specificity. Structural studies demonstrate that the FZD8 CRD has high affinity for Wnt3A, Wnt1, and Wnt2 ligands, enabling robust activation of downstream signaling cascades [@gauger2021].
Seven-Transmembrane Domain: FZD8 contains seven hydrophobic transmembrane helices (TM1-TM7) connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). The transmembrane domain adopts the canonical GPCR fold and couples to heterotrimeric G proteins upon ligand binding. FZD8 preferentially couples to Gαs proteins to activate downstream cAMP signaling, though it can also signal through Gαq and Gαi/o families depending on cellular context.
C-terminal Tail: The intracellular C-terminal tail contains a conserved PDZ domain-binding motif that enables interaction with Dishevelled (DVL) adaptor proteins and other signaling components. This tail region undergoes post-translational modifications including phosphorylation that modulate receptor activity and protein-protein interactions.
FZD8 activates the canonical Wnt/β-catenin pathway through a well-characterized mechanism:
Wnt ligand binding to the FZD8 CRD initiates a signaling cascade involving receptor oligomerization and recruitment of cytoplasmic signaling proteins. FZD8 forms receptor complexes with co-receptors LRP5 or LRP6, which are required for full pathway activation. The FZD8-LRP5/6 complex internalized into signaling endosomes creates a platform for downstream signal transduction [@inestrosa2022].
Upon activation, FZD8 recruits Dishevelled (DVL1, DVL2, DVL3) proteins through interactions between the C-terminal tail of FZD8 and the PDZ domain of DVL. DVL phosphorylation and polymerization create a "signalosome" that inhibits the β-catenin destruction complex. This represents the critical branching point separating canonical from non-canonical Wnt signaling pathways.
In the absence of Wnt signaling, β-catenin is continuously phosphorylated by a destruction complex containing APC, AXIN1/2, GSK3β, and CK1α, targeting it for proteasomal degradation. FZD8-activated DVL disrupts this destruction complex, allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it associates with TCF/LEF transcription factors to activate target gene expression.
Canonical Wnt/β-catenin target genes relevant to neurodegeneration include:
FZD8 also activates non-canonical Wnt pathways independent of β-catenin:
The planar cell polarity (PCP) pathway regulates cytoskeletal dynamics, cell polarity, and tissue patterning. FZD8 activation recruits DVL and activates small GTPases including RAC1 and RHOA, leading to downstream effects on actin cytoskeleton organization, cell migration, and neuronal morphogenesis. In neurons, Wnt/PCP signaling modulates axonal outgrowth, dendritic arborization, and synapse formation through regulation of the cytoskeletal machinery [@cerpa2016].
FZD8 can activate downstream signaling through Gαq-coupled phospholipase C (PLC) activation, leading to intracellular Ca²⁺ release and activation of Ca²⁺-dependent kinases including CaMKII and PKC. This pathway regulates synaptic transmission, neuronal excitability, and gene expression programs important for synaptic plasticity and memory formation.
During early nervous system development, FZD8 participates in dorsal-ventral patterning of the neural tube through gradients of Wnt ligands. FZD8-mediated Wnt signaling establishes morphogen gradients that pattern neuroepithelial cells into distinct progenitor domains along the dorsal-ventral axis, ultimately determining the identities of different neuronal populations [@gauger2021].
FZD8 is expressed in the ventricular and subventricular zones of the developing cortex where neural stem cells reside. Wnt/FZD8 signaling promotes neural progenitor proliferation and inhibits premature neuronal differentiation through β-catenin-dependent transcription. Disruption of FZD8 signaling leads to reduced cortical thickness and altered neuronal layering, demonstrating its essential role in corticogenesis [@buchet2016].
In the developing hippocampus, FZD8 regulates the formation of the dentate gyrus and CA regions. FZD8 expression in neural progenitors of the hippocampal neurogenic niche controls granule cell production and integration. Wnt signaling through FZD8 also guides axonal projections from hippocampal neurons to target regions.
FZD8 localizes to both pre- and postsynaptic compartments in mature neurons where it regulates synaptic development and function. At presynaptic terminals, FZD8 interacts with presynaptic scaffolding proteins to organize active zone machinery. Postsynaptically, FZD8 modulates dendritic spine morphology and synaptic strength through regulation of the actin cytoskeleton and AMPA receptor trafficking [@cerpa2016].
Wnt signaling through FZD8 has been shown to:
Multiple lines of evidence implicate FZD8 and Wnt signaling dysregulation in Alzheimer's disease pathogenesis:
Post-mortem studies of AD brain tissue reveal significant alterations in Wnt pathway components:
FZD8 and Wnt signaling interact with amyloid-β pathology through multiple mechanisms:
Wnt/FZD8 signaling intersects with tau pathology in AD:
Wnt/FZD8 signaling modulates neuroinflammatory responses in AD:
Modulating FZD8 signaling represents a therapeutic strategy for AD:
Wnt/FZD8 signaling is increasingly recognized as relevant to Parkinson's disease pathogenesis:
FZD8 plays critical roles in development and maintenance of dopaminergic neurons:
FZD8 signaling intersects with mitochondrial dysfunction in PD:
The relationship between alpha-synuclein pathology and FZD8:
FZD8 modulates neuroinflammatory processes in PD:
Emerging evidence links FZD8 and Wnt signaling to ALS pathogenesis:
Studies of ALS tissue and models reveal:
FZD8 signaling may explain selective motor neuron vulnerability:
FZD8 in non-neuronal cells affects motor neuron health:
FZD8 exhibits tissue-specific and development stage-specific expression:
Brain Regions:
FZD8 interacts with multiple proteins to execute its signaling functions:
Several studies have examined FZD8 genetic variants in neurodegenerative diseases:
FZD8 represents an attractive therapeutic target for neurodegenerative diseases:
Small Molecule Agonists:
FZD8 as a biomarker in neurodegenerative disease:
Research priorities for FZD8 in neurodegeneration:
FZD8 serves as a critical receptor for Wnt signaling in the nervous system, with essential roles in development, synaptic plasticity, and neuronal survival. Growing evidence demonstrates that FZD8 and Wnt pathway dysregulation contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders. The functional intersection between FZD8 signaling and core pathological features including amyloid-β toxicity, tau phosphorylation, alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation makes FZD8 an attractive therapeutic target. While significant challenges remain in developing brain-penetrant, pathway-specific modulators, the promise of restoring Wnt signaling through FZD8 represents a compelling approach for disease modification in neurodegenerative conditions. Continued investigation of FZD8 biology and therapeutic modulation holds substantial potential for advancing treatment strategies for these devastating disorders.